SCH: INT: Collaborative Research: An intelligent Pervasive Augmented reaLity therapy (iPAL) for Opioid Use Disorder and Recovery
SCH:INT:合作研究:针对阿片类药物使用障碍和恢复的智能普遍增强现实疗法 (iPAL)
基本信息
- 批准号:2019389
- 负责人:
- 金额:$ 26.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Standard Grant
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-10-01 至 2024-09-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Opioid use disorder and addiction are now characterized as a nationwide “opioid epidemic,” with overdoses now the leading cause of injury deaths in the United States. While opioid overdose deaths have increased greatly over the past two decades as compared to other chronic diseases (e.g., heart disease) the development of remote monitoring and management tools and techniques for opioid cravings, recovery, and relapse have not kept pace. There is a critical need to design therapy programs that are discreet, accessible, connected, and personalized by supporting those recovering from Opioid Use Disorder (OUD), beyond conventional therapies. This project develops intelligent Pervasive Augmented reaLity therapies (iPAL) - a technology-enabled OUD intervention that aims to help OUD sufferers manage their cravings to reduce their risk for relapse or overdose. iPAL integrates complementary psychotherapies (cognitive behavioral therapy and heart rate variability biofeedback) with immersive technologies (augmented and mixed reality) to offer convenience, discretion in use, in the moment/real-time through personalized strategies. This work is poised to revolutionize how individuals learn, discover, create, and heal in the broader context of developing treatment strategies for those with OUD. The immediate benefit of the developed system will be iPAL, an appliance for helping those with OUD to experience a better quality of life. The proposed framework has translational potential beyond OUD: serving as a mental health support aid for those suffering from other forms of addiction (e.g., smoking and alcohol), suicidal ideation, post-traumatic stress disorder, and/or severe depression. This work is especially relevant to rural areas where people with OUD often have poor access to services. Even when services are available, stigma is a significant barrier to accessing these traditional addiction services.The novel and potentially transformative nature of this project lies in transcending the foundational theoretical understanding and identification of key technological (e.g., augmented, mixed, and virtual reality), neurophysiological (e.g., functional brain activity, heart rate variability, electrodermal activity), and affective determinants (e.g., positive or negative valence and arousal) of immersion that predict OUD patient experience and subsequently intent (e.g., manage cravings). The team focuses on unobtrusive means (e.g., mobile and wearable technology) to collect real-time physiological parameters to discreetly deliver personalized and interactive evidence-based complementary OUD psychotherapies utilizing Artificial Intelligence (AI) algorithms and immersive technology formats. A series of integrated research efforts is undertaken to advance spatial and affective computing science (technology outcomes) and behavioral science (health outcomes) that will contribute to the following intellectual merits: (1) developing an intelligent system to deliver personalized and interactive evidence-based psychotherapies, (2) fundamentally measuring, modeling, and comparing user engagement using neural signatures and physiological and subjective responses across the reality-virtuality continuum, (3) contributing to augmenting traditional OUD interventions using smart and connected immersive reality technologies, (4) determining the level of immersion most suitable as a mobile and real-time personalized therapeutic intervention, and (5) advancing understanding regarding the role that pervasive and personalized immersive technology plays in at-risk populations.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
阿片类药物使用障碍和成瘾现在被描述为全国性的“阿片类药物流行病”,过量现在是美国伤害死亡的主要原因。 虽然与其他慢性疾病相比,阿片类药物过量死亡在过去二十年中大大增加(例如,心脏病)的远程监测和管理工具和技术的发展,阿片类药物的渴望,恢复和复发没有跟上步伐。 迫切需要设计谨慎,可访问,连接和个性化的治疗方案,通过支持那些从阿片类药物使用障碍(OUD)中恢复的人,超越传统疗法。该项目开发智能普适增强现实疗法(iPAL)-一种技术支持的OUD干预,旨在帮助OUD患者管理他们的渴望,以降低复发或过量的风险。iPAL将补充心理疗法(认知行为疗法和心率变异性生物反馈)与沉浸式技术(增强现实和混合现实)相结合,通过个性化策略提供即时/实时的便利性和使用自由裁量权。这项工作有望在为OUD患者制定治疗策略的更广泛背景下彻底改变个人学习、发现、创造和治愈的方式。开发的系统的直接好处将是iPAL,这是一种帮助OUD患者体验更好生活质量的设备。拟议的框架具有超越OUD的转化潜力:作为对患有其他形式成瘾的人的心理健康支持援助(例如,吸烟和酒精)、自杀意念、创伤后应激障碍和/或严重抑郁症。这项工作对农村地区尤其重要,因为农村地区的开放式学习障碍患者往往很难获得服务。即使在提供服务的情况下,耻辱感也是获得这些传统成瘾服务的一个重大障碍。该项目的新颖性和潜在的变革性在于超越了对关键技术(例如,增强、混合和虚拟现实),神经生理学(例如,功能性脑活动、心率变异性、皮肤电活动),和情感决定因素(例如,正或负效价和唤醒)预测OUD患者体验和随后的意图(例如,管理渴望)。 该团队专注于不引人注目的手段(例如,移动的和可穿戴技术)收集实时生理参数,利用人工智能(AI)算法和沉浸式技术格式谨慎地提供个性化和交互式循证补充OUD心理治疗。 一系列的综合研究工作正在进行,以推进空间和情感计算科学(技术成果)和行为科学(健康成果),这将有助于以下知识的优点:(1)开发一个智能系统,提供个性化和互动的循证心理治疗,(2)从根本上测量,建模,以及使用神经签名和生理和主观反应跨现实-虚拟连续体来比较用户参与,(3)有助于使用智能和连接的沉浸式现实技术来增强传统的OUD干预,(4)确定最适合作为移动的和实时个性化治疗干预的沉浸水平,以及(5)促进对普及和个性化沉浸技术在高危人群中所起作用的理解。该奖项反映了NSF的法定使命,并通过使用基金会的智力价值和更广泛的影响审查标准进行评估,被认为值得支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alain Litwin其他文献
Pictorial Cue Reactivity and Craving Measures in Individuals With Opiate Use Disorder Enrolled in Buprenorphine-Maintenance Program
- DOI:
10.1016/j.ijpsycho.2021.07.395 - 发表时间:
2021-10-01 - 期刊:
- 影响因子:
- 作者:
Erik Ortiz;Ashley Coleman;Irene Pericot-Valverde;Kaileigh Byrne;Alain Litwin;Mohamed Shaban;Estate Sokhadze - 通讯作者:
Estate Sokhadze
M132 - Depression Profiles and Hepatitis C Treatment Outcomes Among Persons who Inject Drugs: The Hero Study
M132 - 注射毒品者的抑郁特征与丙型肝炎治疗结果:英雄研究
- DOI:
10.1016/j.drugalcdep.2023.110412 - 发表时间:
2024-07-01 - 期刊:
- 影响因子:3.600
- 作者:
Snehal Lopes;Irene Pericot-Valverde;Judith Feinberg;Shadi Nahvi;Paula Lum;Lynn Taylor;Judith Tsui;Shruti H Mehta;Brianna Norton;Arthur Kim;Julia Arnsten;James Thrasher;Kimberly Page;Moonseong Heo;Alain Litwin - 通讯作者:
Alain Litwin
S72 - The Association of Self-Report Adherence to Hepatitis C (HCV) Direct-Acting Antiviral (DAA) Therapy With Measured Adherence and Sustained Virologic Response Among People Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy
S72 - 注射毒品者(PWID)接受阿片类激动剂治疗期间,自我报告的丙型肝炎(HCV)直接作用抗病毒(DAA)治疗依从性与测量依从性和持续病毒学应答的关联
- DOI:
10.1016/j.drugalcdep.2023.110183 - 发表时间:
2024-07-01 - 期刊:
- 影响因子:3.600
- 作者:
Snehal Lopes;Irene Pericot-Valverde;Julia Arnsten;Paula Lum;Lynn Taylor;Shruti H Mehta;Judith Tsui;Judith Feinberg;Arthur Kim;Brianna Norton;Kimberly Page;Moonseong Heo;Alain Litwin - 通讯作者:
Alain Litwin
EXPLORATION OF HIV RISK BEHAVIORS AND ATTITUDES TOWARDS PREP AMONG PEOPLE WHO INJECT DRUGS BY GENDER AND SEXUAL ORIENTATION
按性别和性取向对注射毒品者中探索艾滋病病毒风险行为及对暴露前预防(PREP)态度的研究
- DOI:
10.1016/j.drugalcdep.2023.110036 - 发表时间:
2024-07-01 - 期刊:
- 影响因子:3.600
- 作者:
Elenore Bhatraju;Judith Tsui;Andrea C. Radick;Moonseong Heo;Laksika Sivaraj;Shruti H Mehta;Paula Lum;Lynn Taylor;Judith Feinberg;Arthur Kim;Brianna Norton;Irene Pericot-Valverde;Kimberly Page;Alain Litwin - 通讯作者:
Alain Litwin
Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden
关于吸毒者肝炎治疗的建议
- DOI:
10.1016/j.drugpo.2015.11.010 - 发表时间:
2023-01-01 - 期刊:
- 影响因子:4.400
- 作者:
Jason Grebely;Geert Robaeys;Philip Bruggmann;Alessio Aghemo;Markus Backmund;Julie Bruneau;Jude Byrne;Olav Dalgard;Jordan J. Feld;Margaret Hellard;Matthew Hickman;Achim Kautz;Alain Litwin;Andrew R. Lloyd;Stefan Mauss;Maria Prins;Tracy Swan;Martin Schaefer;Lynn E. Taylor;Gregory J. Dore - 通讯作者:
Gregory J. Dore
Alain Litwin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
内源性逆转录病毒MER65-int调控人类胎
盘发育与子宫内膜重塑的功能研究
- 批准号:
- 批准年份:2025
- 资助金额:10.0 万元
- 项目类别:省市级项目
隐秘重组信号序列INT-RSS在T细胞受体基因Tcra重排中的功能和机制研究
- 批准号:32370939
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
HPV16 E7 通过 Int1 蛋白调控 Wnt 信号通路调节肿瘤局部树突状细胞活性
- 批准号:LQ22H160033
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
选择性PPARγ激动剂INT131调控适应性产热和AD-MSCs分化成棕色样脂肪细胞的机制研究
- 批准号:81903680
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
INT复合物调节U snRNA 3'加工的结构基础
- 批准号:31800624
- 批准年份:2018
- 资助金额:28.0 万元
- 项目类别:青年科学基金项目
沉默Int6基因的骨髓间充质干细胞复合生物支架构建血管化腹股沟疝补片及其促补片血管化机制
- 批准号:81371698
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
HIF/Int6调控迟发型EPC体外增殖的机制及其治疗重度子痫前期的可行性
- 批准号:81100439
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
SCH: INT: Collaborative Research: An Intelligent Pervasive Augmented reaLity therapy (iPAL) for Opioid Use Disorder and Recovery
SCH:INT:合作研究:针对阿片类药物使用障碍和恢复的智能普遍增强现实疗法 (iPAL)
- 批准号:
2343183 - 财政年份:2023
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: DeepSense: Interpretable Deep Learning for Zero-effort Phenotype Sensing and Its Application to Sleep Medicine
SCH:INT:合作研究:DeepSense:零努力表型感知的可解释深度学习及其在睡眠医学中的应用
- 批准号:
2313481 - 财政年份:2022
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: Context-Adaptive Multimodal Informatics for Psychiatric Discharge Planning
SCH:INT:合作研究:用于精神病出院计划的上下文自适应多模态信息学
- 批准号:
10573225 - 财政年份:2021
- 资助金额:
$ 26.18万 - 项目类别:
SCH: INT: Collaborative Research: Context-Adaptive Multimodal Informatics for Psychiatric Discharge Planning
SCH:INT:合作研究:用于精神病出院计划的上下文自适应多模态信息学
- 批准号:
10392429 - 财政年份:2021
- 资助金额:
$ 26.18万 - 项目类别:
SCH: INT: Collaborative Research: Using Multi-Stage Learning to Prioritize Mental Health
SCH:INT:协作研究:利用多阶段学习优先考虑心理健康
- 批准号:
2124270 - 财政年份:2021
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: Privacy-Preserving Federated Transfer Learning for Early Acute Kidney Injury Risk Prediction
SCH:INT:合作研究:用于早期急性肾损伤风险预测的隐私保护联合迁移学习
- 批准号:
2014554 - 财政年份:2020
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: Privacy-Preserving Federated Transfer Learning for Early Acute Kidney Injury Risk Prediction
SCH:INT:合作研究:用于早期急性肾损伤风险预测的隐私保护联合迁移学习
- 批准号:
2014552 - 财政年份:2020
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: An intelligent Pervasive Augmented reaLity therapy (iPAL) for Opioid Use Disorder and Recovery
SCH:INT:合作研究:针对阿片类药物使用障碍和恢复的智能普遍增强现实疗法 (iPAL)
- 批准号:
2013651 - 财政年份:2020
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: An Intelligent Pervasive Augmented reaLity therapy (iPAL) for Opioid Use Disorder and Recovery
SCH:INT:合作研究:针对阿片类药物使用障碍和恢复的智能普遍增强现实疗法 (iPAL)
- 批准号:
2013122 - 财政年份:2020
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant
SCH: INT: Collaborative Research: DeepSense: Interpretable Deep Learning for Zero-effort Phenotype Sensing and Its Application to Sleep Medicine
SCH:INT:合作研究:DeepSense:零努力表型感知的可解释深度学习及其在睡眠医学中的应用
- 批准号:
2014431 - 财政年份:2020
- 资助金额:
$ 26.18万 - 项目类别:
Standard Grant